期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Melatonin: A Powerful Integrative Adjunctive Agent for Oncology
1
作者 Robert Schettig trevor sears +10 位作者 Matthew Klein Ruth Tan-Lim Ronald Matthias Christopher Aussems Michael Hummel Rory sears Zachary Poteet Daniel Warren John Oertle Connor Coffin Dino Prato 《Journal of Cancer Therapy》 2020年第9期571-596,共26页
Melatonin is an established hormone supplement and has been well recognized for its effect on the circadian cycle to improve sleep, REM (rapid eye movement), and aiding in jetlag recovery. The utility of melatonin ext... Melatonin is an established hormone supplement and has been well recognized for its effect on the circadian cycle to improve sleep, REM (rapid eye movement), and aiding in jetlag recovery. The utility of melatonin extends beyond sleep aid, however. This hormone also possesses less well-known antioxidant action and even robust anticancer activity. Melatonin may be a key supplement for addressing age-related neurologic decline while serving as a valuable adjunctive cancer treatment that reduces drug resistance in tumors and downregulates angiogenesis. In immunotherapy, melatonin activates Natural Killer (NK) cells nested within tumoral tissue and does not have the side effect profile of other immunoreactive agents used for chemotherapy. Since melatonin is found in high concentrations in the brain and other hormone-linked tissues, the relevance of melatonin is increased for the treatment of estrogen-linked cancers. The immunomodulatory effect of melatonin may also help with chronic inflammation seen in patients with autoimmune disorders. All of these effects together represent a unique and versatile therapeutic agent for integrative medicine. No other commercially available drug possesses all of these therapeutic mechanisms while having a very minimal side </span><span style="font-family:Verdana;">effect profile and being considered overall to be safe to use. Currently, melatonin is underutilized in medicine, especially in the field of integrative oncology and represents a crucial supportive adjuvant to improve the lives of patients</span><span style="font-family:Verdana;">. 展开更多
关键词 MELATONIN ONCOLOGY Immunotherapy Chronic Inflammation Autoimmune Envita Antioxidant Anticancer ANTIANGIOGENESIS TELOMERASE Metastasis ANTI-PROLIFERATION Pro-Apoptosis Immune System Activation Cancer Adjuvant Chemotherapy Synergy
下载PDF
COVID-19 Patient with Multifocal Pneumonia and Respiratory Difficulty Resolved Quickly: Possible Antiviral and Anti-Inflammatory Benefits of Quercinex (Nebulized Quercetin-NAC) as Adjuvant
2
作者 Robert Schettig trevor sears +9 位作者 Matthew Klein Ruth Tan-Lim Ronald Matthias Jr. Christopher Aussems Michael Hummel Rory sears Zachary Poteet Daniel Warren John Oertle Dino Prato 《Advances in Infectious Diseases》 2020年第3期45-55,共11页
<strong>Background:</strong> SARS-CoV-2 (COVID-19) is a viral pandemic with no current vaccine or effective treatment. Hydroxychloroquine and azithromycin are not without cardiovascular risk or complicatio... <strong>Background:</strong> SARS-CoV-2 (COVID-19) is a viral pandemic with no current vaccine or effective treatment. Hydroxychloroquine and azithromycin are not without cardiovascular risk or complications, and these treatments can fail to aid in full recovery from COVID-19. As new treatments become approved for the pandemic, an inexpensive, non-toxic, and safe adjunctive therapy is needed. <strong>Case Presentation:</strong> A 59-year-old male presented with respiratory symptoms. Chest X-ray revealed classic indications of COVID-19 pneumonia. A PCR nasopharyngeal swab test confirmed a COVID-19 infection and hospital doctors prescribed Rocephin, azithromycin, and hydroxychloroquine. The patient was then prescribed Quercinex, a nebulized formula of quercetin-(cyclodextrin) (20 mg/mL) and N-acetylcysteine (100 mg/mL) three times daily for 14 days by physicians at Envita Medical Center for continued COVID-19 respiratory symptoms. Following 30 minutes after each nebulization treatment, the patient experienced immediate deep breathing relief that lasted for multiple hours. Within the following 48 hours after the first treatment, respiratory symptoms continued to diminish and resolve quickly. Finally, post-treatment follow-up chest X-rays revealed no pulmonary fibrosis (scarring) and clear lung fields. <strong>Conclusion: </strong>The Quercinex formula appeared to greatly alleviate the unresolved respiratory symptoms rapidly. Several mechanisms of the formula, namely antiviral and anti-inflammatory action, with direct administration via nebulizer to the deep lung tissue, could potentially explain the fast and complete recovery. We recommend that the Quercinex formula be considered for further clinical study as an adjuvant or on its own for COVID-19 and possibly other viral pulmonary conditions. 展开更多
关键词 Quercetin N-Acetylcysteine (NAC) SARS-CoV-2 (COVID-19) Quercinex Envita Zinc PNEUMONIA Case Study Severe Acute Respiratory Syndrome Flavonoid Lung ANTIVIRAL Human
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部